Genovate Biotechnology Co Ltd Asset Resilience Ratio
Genovate Biotechnology Co Ltd asset resilience ratio. Genovate Biotechnology Co Ltd (4130) has an Asset Resilience Ratio of 20.77% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 4130 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Genovate Biotechnology Co Ltd (2015–2025)
Asset resilience ratio of Genovate Biotechnology Co Ltd from 2015 to 2025. This chart shows how Genovate Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Read 4130 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Genovate Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Genovate Biotechnology Co Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$312.92 Million | 20.77% |
| Total Liquid Assets | NT$312.92 Million | 20.77% |
Asset Resilience Insights
- Good Liquidity Position: Genovate Biotechnology Co Ltd maintains a healthy 20.77% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Genovate Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Genovate Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Genovate Biotechnology Co Ltd Asset Resilience Ratio by Year (2015–2025)
Genovate Biotechnology Co Ltd asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Genovate Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.77% | NT$312.92 Million ≈ $9.86 Million |
NT$1.51 Billion ≈ $47.46 Million |
+1.92pp |
| 2024-12-31 | 18.86% | NT$299.87 Million ≈ $9.45 Million |
NT$1.59 Billion ≈ $50.10 Million |
-3.59pp |
| 2023-12-31 | 22.45% | NT$359.27 Million ≈ $11.32 Million |
NT$1.60 Billion ≈ $50.42 Million |
+3.09pp |
| 2022-12-31 | 19.36% | NT$302.88 Million ≈ $9.54 Million |
NT$1.56 Billion ≈ $49.29 Million |
+6.76pp |
| 2021-12-31 | 12.60% | NT$190.98 Million ≈ $6.02 Million |
NT$1.52 Billion ≈ $47.75 Million |
0.00pp |
| 2020-12-31 | 12.60% | NT$197.98 Million ≈ $6.24 Million |
NT$1.57 Billion ≈ $49.49 Million |
-3.74pp |
| 2019-12-31 | 16.35% | NT$257.10 Million ≈ $8.10 Million |
NT$1.57 Billion ≈ $49.56 Million |
+1.82pp |
| 2018-12-31 | 14.52% | NT$252.10 Million ≈ $7.94 Million |
NT$1.74 Billion ≈ $54.69 Million |
-0.02pp |
| 2017-12-31 | 14.54% | NT$296.92 Million ≈ $9.35 Million |
NT$2.04 Billion ≈ $64.33 Million |
-3.82pp |
| 2016-12-31 | 18.37% | NT$486.00 Million ≈ $15.31 Million |
NT$2.65 Billion ≈ $83.37 Million |
-3.02pp |
| 2015-12-31 | 21.39% | NT$538.40 Million ≈ $16.96 Million |
NT$2.52 Billion ≈ $79.31 Million |
-- |
About Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more